

Datasheet for ABIN7274150

**CD37 Protein (AA 113-240) (Fc Tag)****2** Images[Go to Product page](#)

## Overview

|                               |  |
|-------------------------------|--|
| Quantity:                     | 100 µg                                     |
| Target:                       | CD37 (TSPAN26)                             |
| Protein Characteristics:      | AA 113-240                                 |
| Origin:                       | Human                                      |
| Source:                       | HEK-293 Cells                              |
| Protein Type:                 | Recombinant                                |
| Purification tag / Conjugate: | This CD37 protein is labelled with Fc Tag. |

## Product Details

|                  |  |
|------------------|--|
| Purpose:         | Human CD37 Protein   |
| Sequence:        | Ala113-Asn240  |
| Characteristics: | Recombinant Human CD37 Protein is expressed from HEK293 with hFc tag at the N-Terminus. It contains Ala113-Asn240. |
| Purity:          | > 95 % as determined by Tris-Bis PAGE, > 95 % as determined by HPLC  |
| Sterility:       | 0.22 µm filtered   |
| Endotoxin Level: | Less than 1EU per µg by the LAL method.  |

## Target Details

|                   |   |
|-------------------|---|
| Target:           | CD37 (TSPAN26)                            |
| Alternative Name: | CD37 ( <a href="#">TSPAN26 Products</a> ) |

## Target Details


|                   |  |
|-------------------|--|
| Background:       | CD37 is a tetraspanin expressed prominently on the surface of B cells. It is an attractive molecular target exploited in the immunotherapy of B cell-derived lymphomas and leukemia. Currently, several monoclonal antibodies targeting CD37 as well as chimeric antigen receptor-based immunotherapies are being developed and investigated in clinical trials. Given the unique role of CD37 in the biology of B cells, it seems that CD37 constitutes more than a docking point for monoclonal antibodies, and targeting this molecule may provide additional benefit to relapsed or refractory patients. |
| Molecular Weight: | 41.9 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Tris-Bis PAGE result.   |
| Pathways:         | <a href="#">Positive Regulation of Immune Effector Process</a> , <a href="#">Production of Molecular Mediator of Immune Response</a>   |

## Application Details

|               |                       |
|---------------|-----------------------|
| Restrictions: | For Research Use only |
|---------------|-----------------------|


## Handling

|                  |   |
|------------------|---|
| Format:          | Lyophilized   |
| Reconstitution:  | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/mL is recommended. Dissolve the lyophilized protein in distilled water.  |
| Buffer:          | Lyophilized from 0.22µm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.  |
| Storage:         | -20 °C,-80 °C   |
| Storage Comment: | -20 to -80°C for 12 months as supplied from date of receipt., -80°C for 3-6 months after reconstitution., 2-8°C for 2-7 days after reconstitution., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
| Expiry Date:     | 12 months   |



SDS-PAGE

**Image 1.** Human CD37 on Tris-Bis PAGE under reduced condition. The purity is greater than 95 % .



Size-exclusion chromatography-High Pressure Liquid Chromatography

**Image 2.** The purity of Human CD37 is greater than 95 % as determined by SEC-HPLC.